Comparison of the action of NSC 680410 and STI571 in chronic myelogenous leukemia cells in vitro.

被引：0
|
作者：
Mow, BM
Hallgren, CG
Svingen, PA
Tefferi, A
Sausville, EA
Kaufmann, SH
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Div Oncol Res, Rochester, MN USA
[3] NCI, Dev Therapeut Program, Bethesda, MD 20892 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1493
引用
收藏
页码：346A / 346A
页数：1
相关论文
共 50 条
  • [21] Restoration of sensitivity to STI571 in ST1571-resistant chronic myeloid leukemia cells
    Tipping, AJ
    Mahon, FX
    Lagarde, V
    Goldman, JM
    Melo, JV
    BLOOD, 2001, 98 (13) : 3864 - 3867
  • [22] Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis
    Beham-Schmid, C
    Apfelbeck, U
    Sill, H
    Tsybrovsky, O
    Höfler, G
    Haas, OA
    Linkesch, W
    BLOOD, 2002, 99 (01) : 381 - 383
  • [23] Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571
    Wolff, NC
    Ilaria, RL
    BLOOD, 2001, 98 (09) : 2808 - 2816
  • [24] Effects of the tyrosine kinase inhibitor Imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia
    Thiele, J
    Kvasnicka, HM
    Schmitt-Graeff, A
    Kriener, S
    Engels, K
    Staib, P
    Griesshammer, M
    Waller, CF
    Ottmann, OG
    Hansmann, M
    HISTOLOGY AND HISTOPATHOLOGY, 2004, 19 (04) : 1277 - 1288
  • [25] Troxatyl and STI571 combination therapy for chronic myeloid leukemia: Preclinical in vitro and in vivo evaluation.
    Orsolic, N
    Giles, F
    Beran, M
    Cortes, J
    Albitar, M
    Kantarjian, H
    Verstovsek, S
    BLOOD, 2002, 100 (11) : 786A - 786A
  • [26] Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines
    Avramis, IA
    Laug, WE
    Sausville, EA
    Avramis, VI
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (04) : 307 - 318
  • [27] Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
    Graham, SM
    Jorgensen, HG
    Allan, E
    Pearson, C
    Alcorn, MJ
    Richmond, L
    Holyoake, TL
    BLOOD, 2002, 99 (01) : 319 - 325
  • [28] The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations
    Marin, D
    Marktel, S
    Bua, M
    Armstrong, L
    Goldman, JM
    Apperley, JF
    Olavarria, E
    HAEMATOLOGICA, 2002, 87 (09) : 979 - 988
  • [29] ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis
    A Nakajima
    T Tauchi
    K Ohyashiki
    Leukemia, 2001, 15 : 989 - 990
  • [30] ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis
    Nakajima, A
    Tauchi, T
    Ohyashiki, K
    LEUKEMIA, 2001, 15 (06) : 989 - 990
12345